Literature DB >> 30098673

Sharing and the Provision of "Cost-Ineffective" Life-Extending Services to Less Severely Ill Patients.

Jeff Richardson1, Angelo Iezzi2, Aimee Maxwell2.   

Abstract

BACKGROUND: Cost-utility analysis prioritizes services using cost, life-years, and the health state utility of the life-years. Nevertheless, a significant body of evidence suggests that the public would prefer more variables to be considered in decision making and at least some sharing of the budget with services for severe conditions that are not cost-effective because of their high cost.
OBJECTIVES: To examine whether this preference for sharing persists for less severe conditions when both cost effectiveness and illness severity would indicate that resources should be allocated to other services.
METHODS: Survey respondents were asked to divide a budget between two patients facing life-threatening illnesses. The severity of the illnesses differed and the price of treatment was varied.
RESULTS: Sharing occurred in all scenarios including scenarios in which the illness was less severe and services were not cost-effective. Results are consistent with behavior commonly observed in other contexts.
CONCLUSIONS: Results suggest that sharing per se is important and that the public would support some funding of cost-ineffective services for less severe health problems.
Copyright © 2018 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost-utility analysis; orphan services; reciprocity; sharing; social preferences

Mesh:

Year:  2018        PMID: 30098673     DOI: 10.1016/j.jval.2017.12.024

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  1 in total

1.  What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK.

Authors:  Liz Morrell; James Buchanan; Sian Rees; Richard W Barker; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2021-08-19       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.